India has ₹8,447.4 crore in outstanding medicine overcharging claims, according to figures reported by the National Pharmaceutical Pricing Authority (NPPA) as of March 31, 2026. The amount represents about 84% of the cumulative ₹10,029.8 crore demanded from companies, including interest, in cases covered by the regulator's records.
The NPPA had recovered ₹1,582.4 crore by the same date. The authority has noted that the figures are subject to reconciliation.
The outstanding claims come amid renewed scrutiny of medicine pricing. On October 12, 2026, the Centre informed the Supreme Court that it had decided to cap trade margins at 30% for anti-cancer medicines.
A Bench comprising Justices Vikram Nath and Sandeep Mehta questioned why similar restrictions could not be extended to other medicines and medical products. The court highlighted substantial differences between supply prices and the prices charged to patients and asked the government to consider broader measures to regulate medicine prices. The matter is scheduled for another hearing on October 27.
Trade margins and illegal overcharging are distinct issues. High trade margins are not necessarily unlawful, but charging above regulated prices can violate the Drugs (Prices Control) Orders (DPCO), which govern medicine pricing in India.
Established in 1997, the NPPA is responsible for monitoring and regulating drug prices and pursuing cases involving violations of applicable price controls. Its records include cases dating back to 1979.
Under the 2013 DPCO, certain pricing violations can also attract penalties. The outstanding amount highlights the scale of claims still being pursued by the regulator, while the Supreme Court's proceedings have brought wider questions about medicine affordability and pricing practices into focus.

AdvertisementThe Puranic